Search & Analyze

Akums Drugs & Pharmaceuticals Ltd.

735.00−6.10 (−0.82%)

BSE · 30 Oct, 4:01 PM

: ₹11,519.67 Cr
: 39.49
: 3,981
: ₹755.00 - ₹723.05
: ₹839.25 - ₹410.10

Akums Drugs & Pharmaceuticals Ltd. (AKUMS) share price closed at ₹735.00 on the BSE on Friday, October 30, 2026, down by 0.82% from its of ₹741.10. In that session AKUMS reached a of 755.00 and of 723.05. The for the session was 732.59. The stands at 764.63 and is at 602.80. Looking at , the stock ended the session moving sideways.

Stock Overview

₹741.35

₹741.10

₹732.59

₹764.63

Price 3.88% below

₹602.80

Price 21.93% above

Key Fundamentals

: 11,519.67 Cr₹11.52 Thousand Crore
: 18.53
: 39.49
: 3.37
: 216.98
: 700.11 Cr₹700.11 Crore
: 0.41 %
Sector
Industry: Pharmaceuticals & Drugs
: 8.06
: 0.02

Industry Comparison

Ratio	Company	Sector
	39.49	44.77
	0.02	0.20
	3.37	4.61
	3.25	1.81
	0.41 %	0.11 %
Operating Margin	11.98 %	19.15 %

Sector figures are the median of 154 listed Healthcare companies.

Peer Comparison

Name
SUN PHARMA. SUNPHARMA	1,778.25	38.91	4,26,661.74	0.90	1,995.07	-36.16%	16,198.71	11.88%	19.11
DIVI'S LAB. DIVISLAB	9,715.00	88.17	2,57,902.73	0.31	902.00	65.50%	3,080.00	27.80%	21.51
TORRENT PHAR TORNTPHARM	4,635.15	83.01	1,76,306.21	0.82	534.00	-9.64%	4,979.00	50.79%	19.27
LAURUSLABS LAURUSLABS	2,392.00	96.46	1,29,242.68	0.08	436.19	124.27%	2,206.37	33.44%	18.20
ZYDUSLIFE ZYDUSLIFE	1,244.00	27.50	1,24,089.48	0.08	990.20	-34.90%	8,017.00	21.96%	21.39
DR.REDDY'S DRREDDY	1,350.20	40.25	1,12,698.53	0.59	913.20	-31.69%	8,697.80	-1.48%	13.75
CIPLA LTD. CIPLA	1,380.00	38.48	1,11,488.55	0.94	851.51	-37.08%	7,403.93	-2.44%	16.00
Akums Drugs & Pharmaceuticals Ltd. AKUMS	735.00	39.49	11,519.67	0.41	100.98	56.11%	1,166.63	13.93%	14.77

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	944.21	1,019.11	1,033.09	1,010.41	1,055.55	1,024.03	1,017.53	1,159.59	1,157.87	1,166.63
Expenses	941.22	891.10	911.90	889.05	961.63	895.06	923.05	1,012.73	1,006.15	991.95
	2.99	128.02	121.19	121.37	93.91	128.97	94.48	146.86	151.72	174.68
	0.32%	12.56%	11.73%	12.01%	8.90%	12.59%	9.28%	12.66%	13.10%	14.97%
	10.46	6.55	17.17	19.34	25.76	26.73	32.36	16.10	33.51	30.38
Interest	12.38	13.02	11.90	5.13	4.54	23.13	23.30	23.74	23.89	24.76
	33.95	34.06	34.86	44.52	40.00	36.92	37.86	39.65	40.12	41.07
	-32.88	87.48	91.59	91.05	75.14	95.65	65.67	99.57	121.22	139.24
	-20.03%	30.03%	27.23%	27.17%	-99.11%	32.37%	34.99%	32.03%	32.89%	27.48%
	-41.32	60.17	65.21	65.18	147.62	63.48	40.78	66.32	84.61	100.01
	-2.89	4.21	4.26	4.26	9.64	4.15	2.66	4.33	5.53	6.53

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
INCOME :
	3,671.89	3,654.82	4,178.18	4,118.16	4,359.02
	3,671.89	3,654.82	4,178.18	4,118.16	4,359.02
EXPENDITURE :
Increase/Decrease in Stock	-87.74	24.04	12.34	-1.65	13.84
Raw Material Consumed	2,432.80	2,249.87	2,537.90	2,435.08	2,499.68
Power & Fuel Cost	110.22	147.41	160.80	164.05	184.29
Employee Cost	507.76	590.13	646.86	715.82	753.82
Other Manufacturing Expenses	102.23	108.97	102.11	98.18	110.90
General and Administration Expenses	78.24	109.07	104.84	102.93	124.56
Selling and Distribution Expenses	51.93	54.40	55.97	55.36	53.69
Miscellaneous Expenses	568.19	76.95	434.38	87.77	96.21
	3,763.61	3,360.84	4,055.20	3,657.55	3,836.99
Operating Profit (Excl OI)	-91.72	293.98	122.98	460.61	522.02
	22.63	90.07	34.03	55.99	128.73
	-69.09	384.06	157.01	516.60	650.75
Interest	16.66	46.25	50.61	34.60	94.07
PBDT	-85.74	337.81	106.40	482.00	556.68
	94.68	112.81	125.64	153.45	154.55
Profit Before Taxation & Exceptional Items	-180.42	225.00	-19.24	328.56	402.13
Exceptional Income / Expenses	-12.98	-74.50	-26.03	16.70	-20.02
	-193.20	150.30	-45.28	345.25	382.10
Provision for Tax	57.68	52.48	-46.07	1.48	125.70
	-250.87	97.82	0.79	343.78	256.40
Extra items				0.00	0.00
Minority Interest	-1.66	-2.96	-4.83	-5.60	-1.21
Consolidated Net Profit	-252.54	94.86	-4.04	338.18	255.19
Profit Balance B/F	832.38	557.63	638.54	630.85	1,829.43
Appropriations	579.85	652.48	634.50	969.02	2,084.62
Equity Dividend %					150.00%
	-35.30	6.63	-0.28	22.09	16.67
Adjusted EPS	-17.65	6.63	-0.28	22.09	16.67

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	14.31	28.61	28.61	30.62	30.62
Total Reserves	607.67	688.58	680.89	3,016.39	3,282.73
Reserve excluding Revaluation Reserve	607.67	688.58	680.89	3,016.39	3,282.73
Revaluation reserve	0.00	0.00
	621.98	717.19	709.50	3,047.01	3,313.35
Minority Interest	3.20	6.19	10.99	16.60	17.77
Secured Loans	13.33	115.50	78.30
Deferred Tax Assets / Liabilities	20.45	-6.22	-110.91	-189.45	-153.18
Other Long Term Liabilities	1,094.90	1,110.56	1,463.85	101.57	954.77
Long Term Provisions	23.93	26.23	31.03	35.90	48.61
Total Non-Current Liabilities	1,152.61	1,246.07	1,462.26	-51.98	850.20
Trade Payables	589.67	567.14	532.13	642.79	602.16
Other Current Liabilities	238.09	246.17	252.69	179.70	345.30
Short Term Borrowings	337.93	387.55	367.70	13.66	72.95
Short Term Provisions	106.72	64.71	58.03	57.61	74.35
Total Current Liabilities	1,272.42	1,265.57	1,210.55	893.75	1,094.76
Total Liabilities	3,050.20	3,235.01	3,393.30	3,905.38	5,276.08
Gross Block	1,541.56	1,714.77	1,893.01	2,251.58	2,444.92
Less: Accumulated Depreciation	521.02	617.46	702.25	854.21	989.12
	1,020.54	1,097.31	1,190.77	1,397.37	1,455.80
	30.82	102.99	195.13	159.62	176.66
Non Current Investments	0.39	0.14	0.14	0.14	0.14
Long Term Investment	0.39	0.14	0.14	0.14	0.14
Long Term Loans & Advances	86.10	96.39	56.36	61.41	75.88
Other Non Current Assets	20.49	13.85	9.74	9.06	7.00
Total Non-Current Assets	1,158.58	1,310.85	1,452.42	1,630.77	1,716.22
Inventories	722.45	729.80	630.43	680.93	755.71
Sundry Debtors	884.31	845.09	833.81	770.30	796.56
Cash and Bank	102.85	149.99	277.05	576.45	1,680.60
Other Current Assets	9.49	14.71	30.09	31.94	23.52
Short Term Loans and Advances	144.96	139.29	169.40	214.99	303.46
Total Current Assets	1,864.06	1,878.87	1,940.78	2,274.61	3,559.86
Net Current Assets (Including Current Investments)	591.65	613.31	730.23	1,380.86	2,465.10
Total Assets	3,050.20	3,235.01	3,393.30	3,905.38	5,276.08
	97.51	81.54	88.62	91.90	99.40
Total Debt	357.95	536.97	491.56	13.66	72.95
	86.95	50.13	49.59	199.01	216.41
Adjusted Book Value	43.47	50.13	49.59	199.01	216.41

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
	-193.20	150.30	-45.28	345.25	382.10
Adjustment	631.42	157.73	556.09	171.56	164.26
Changes In working Capital	-351.56	-34.33	49.87	29.62	722.21
Cash Flow after changes in Working Capital	86.67	273.69	560.68	546.43	1,268.57
Cash Flow from Operating Activities	31.85	176.63	498.26	465.20	1,181.20
Cash Flow from Investing Activities	-234.82	-304.70	-330.42	-547.84	-930.27
Cash Flow from Financing Activitie	236.04	124.54	-108.02	72.79	33.88
Net Cash Inflow / Outflow	33.07	-3.53	59.82	-9.86	284.81
Opening Cash & Cash Equivalents	22.07	55.14	51.61	111.05	101.19
Cash & Cash Equivalent on Amalgamation / Take over / Merger			-0.38
Closing Cash & Cash Equivalent	55.14	51.61	111.05	101.19	386.01

Ratios

Valuation

39.49

3.37

14.16

2.56

18.53

216.98

Profitability

8.06

14.77

5.59

11.98

5.88

Leverage & Liquidity

0.02

3.25

5.06

Returns

0.41

0.95

Shareholding Pattern

Numbers in percentages

Particulars	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26	Sep '26
	75.26	75.26	75.26	75.26	75.26	75.26	75.26	75.26	75.26
	14.58	13.08	13.17	13.09	11.56	15.55	15.72	15.35	15.58
	10.16	11.66	11.58	11.66	13.19	9.19	9.02	9.39	9.16
	24.74	24.74	24.74	24.74	24.74	24.74	24.74	24.74	24.74
No. of Shareholders	57,531	68,410	69,366	69,424	75,365	76,869	72,589	70,289	67,618

Mutual Funds Invested(22)

Based on each fund's latest monthly portfolio · Sep 2026

A total of 13 active funds hold 7.53% in Akums Drugs & Pharmaceuticals Ltd., contributing to ₹969 Cr of holdings

Fund				As of
FT Franklin India Opportunities Fund - Growth - Direct PlanEquity - Thematic Fund - Other	207.36	2.17	25,33,367	Sep '26
FT Franklin India Small Cap Fund - Growth - Direct PlanSmall cap Fund	173.30	1.22	21,17,232	Sep '26
ID Bandhan Small Cap Fund - Growth - Direct PlanSmall cap Fund	145.19	0.40	17,73,851	Sep '26
IP ICICI Prudential Healthcare Fund - Growth - Direct PlanPharma & Health Care	131.36	1.91	16,04,863	Sep '26
NI Nippon India Pharma Fund - Growth - Direct PlanPharma & Health Care	110.63	1.21	13,51,672	Sep '26
FT Franklin India Multi Cap Fund - Growth - Direct PlanMulti Cap Fund	85.36	1.67	10,42,859	Sep '26
AS Altiva Equity Ex-Top 100 Long-Short Fund - Growth - Direct PlanEquity - Ex-Top 100 Long-Short Fund	53.03	3.45	6,47,869	Sep '26
FT Templeton India Value Fund - Growth - Direct PlanEquity - Value Fund	36.83	2.04	4,50,000	Sep '26
OB Old Bridge Flexi Cap Fund - Growth - Direct PlanFlexi Cap Fund	12.60	2.80	1,54,000	Sep '26
JB JioBlackRock Flexi Cap Fund - Growth - Direct PlanFlexi Cap Fund	8.90	0.28	1,08,715	Sep '26

Corporate Actions

Showing: All

Date	Type	Details
2026-10-28	Board Meeting	Quarterly Results
2026-08-05	Board Meeting	Quarterly Results
2026-06-18	AGM

Insider Trading

Date	Person	Category	Transaction Type	Shares	Value (₹)

No insider trading data available.

Sector Overview

HealthcarePharmaceuticals & Drugs

Akums Drugs & Pharmaceuticals Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

9 members across the board and senior leadership

Dharamvir Malik

Company Secretary & Compliance Officer

—

Sanjeev Jain

Managing Director

₹8.66 Cr

Mar '26

Sandeep Jain

Managing Director

₹8.62 Cr

Mar '26

Sanjay Sinha

Whole Time Director

₹1.43 Cr

Mar '26

Sunil Kumar Thakur

Non Executive Director

—

Kewal Handa

Non Executive Independent Director

₹15.00 L

Mar '26

Matangi Gowrishankar

Non Executive Independent Director

₹16.00 L

Mar '26

Satwinder Singh

Non Executive Independent Director

₹14.00 L

Mar '26

Anil Amin

Non Executive Independent Director

₹9.00 L

Mar '26

AKUMS Latest News

News

10 of 10 articles

EQUITY3 Sept 2026 · 17:09

Akums Drugs and Pharmaceuticals informs about ESG rating

EQUITY10 Aug 2026 · 17:26

Akums Drugs and Pharmaceuticals informs about newspaper advertisements

EQUITY10 Aug 2026 · 10:37

Akums Drugs climbs on reporting 58% jump in Q1 consolidated net profit

The total consolidated income of the company has increased by 13.92% at Rs 1,197.01 crore for Q1FY27

COMPANY10 Aug 2026 · 10:30

Akums Drugs reports 58% jump in Q1 consolidated net profit

The total consolidated income of the company has increased by 13.92% at Rs 1,197.01 crore for Q1FY27

COMPANY24 Jul 2026 · 09:25

Akums Drugs’ arm gets nod to acquire Oriflame India’s manufacturing business

The said acquisition is expected to be completed by August 31, 2026

EQUITY19 Jun 2026 · 16:29

Akums Drugs and Pharmaceuticals informs about annual report

EQUITY19 Jun 2026 · 13:08

Akums Drugs and Pharmaceuticals informs about newspaper advertisements

EQUITY19 Jun 2026 · 12:26

Akums Drugs and Pharmaceuticals informs about annual report

EQUITY16 Jun 2026 · 15:40

Akums Drugs and Pharmaceuticals informs about press release

EQUITY18 May 2026 · 16:51

Akums Drugs and Pharmaceuticals inform about update on disruption in operations

Akums Drugs & Pharmaceuticals Ltd.

Stock Overview

Price chart

Peer Comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Valuation

Profitability

Leverage & Liquidity

Returns

Shareholding Pattern

Mutual Funds Invested(22)

Corporate Actions

Insider Trading

Sector Overview

Company Profile

Key Management

AKUMS Latest News

News